Last updated: 2026-09-16 09:04:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Erasca, Inc. (ERAS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16.20, with a market capitalisation of $5.65B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.59 to $24.28. This page covers its latest market performance, valuation, price trends and company information.
$5.65B | |
$16.15 | |
$24.47 | |
$1.01 | |
$16.25 | |
6.42K | |
4.59M | |
-- | |
$24.28 | |
$1.59 | |
-- | |
-- |
Erasca, Inc. (ERAS) is trading at $16.20 in pre-market trading as of 2026-09-16 08:53:00, down 0.30% ($0.05) from the previous close of $16.25
Pre-market trading shows how investors are pricing ERAS before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Erasca, Inc. (ERAS) moved from $16.19 to $16.20, representing a gain of 0.07% ($0.01).
The stock traded between $15.37 and $17.25 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 4.08 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 64.4%
ERAS is currently trading at $16.20, placing it 64.4% of the way from its 52-week low of $1.59 to its 52-week high of $24.28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 103 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Erasca, Inc. (ERAS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.